call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Global Biosimilars Market
Inquire Before Buying Request for Sample

Global Biosimilars Market

Home Healthcare And Pharmaceutical Global Biosimilars Market

Biosimilars Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Product (Monoclonal Antibodies (Infliximab, Rituximab, Trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin); By Disease Indication (Cancer, Auto Immune Diseases, Chronic Diseases, Blood Disorders, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA))

  • Published Date: November 2022
  • Report ID: BWC22532
  • Available Format: PDF
  • Page: 240

Report Overview

Rising prevalence of autoimmune diseases, rising adoption of cost-effective biosimilars, patent expiry on many blockbuster biological drugs, and rising government spending on healthcare could boost the growth of Global Biosimilars Market at a robust growth rate during the forecast period between 2023 and 2029.

Global Biosimilars Market - Industry Trends & Forecast Report, 2029

Global biosimilars market size is estimated at USD 28.88 billion in 2022. During the forecast period between 2023 and 2029, the size of global biosimilars market is projected to grow at a CAGR of 21.3%, reaching a value of USD 115.39 billion by 2029. The growth of the global biosimilars market is being driven by the biosimilars' affordability in treating a variety of chronic diseases that are common among the world's population. The adoption of biosimilars is expected to increase quickly due to the rising prevalence of chronic diseases among the population and the recent approval of numerous biosimilars in many countries by regulatory authorities. The demand for biosimilars is increasing globally due to growing awareness of the availability of biosimilar medications and their efficacy in treating a variety of disorders. Biosimilars are an effective treatment option for several chronic diseases, including kidney failure, diabetes, cancer, and cardiovascular disease, which is expected to fuel the growth of global biosimilars market during the period in analysis.

Global Biosimilars Market

Global Biosimilars Market- Overview

A biotherapeutic product that is similar to a reference biologic drug is referred to as a biosimilar, also known as a follow-on biologic. It has a complex molecular structure and is made from living things or cells. Manufacturers rely on regulatory authority approval to launch the production of biosimilars after the patent on a biologic drug expires. A biological drug must be demonstrated to be similar in terms of quality, safety, and efficacy to be labeled as a biosimilar. Biosimilars are more expensive than generic medications because their production requires greater investment in R&D and is more complicated.

Growth Drivers

Cost-effectiveness of biosimilars

Increased demand for biosimilars will promote business growth in the future. The American Journal of Managed Care (AJMC) reports that biosimilar drugs are priced 20% to 30% lower than reference biologic drugs. According to the AJMC study, the use of these drugs will result in USD 102.5 billion in savings between 2014 and 2025. Their lower cost of results in effective patient treatment as well as treatment cost-cutting will be a major growth factor. Furthermore, price competition between follow-on biologics and reference drugs has a downward effect on the prices of reference biologics, thereby accelerating business growth.

Rising proficiencies in R&D

Rising R&D spending, particularly in developed and developing economies, will create more lucrative market growth opportunities for drugs, medical instruments, and devices. R&D abilities have resulted in advancements in medical technology and an improvement in the quality of healthcare facilities. The growing number of screening tests for research abilities has broadened the scope of growth even further. In the coming years, it is expected that regulatory reforms in major countries, including the US, China, and Japan, will increase the adoption of biosimilars. Over 60 biosimilar brands have already received European approval, which make up about 50% of the market. Seven biosimilars were given US FDA approval in 2018. Because of this, it is expected that regulatory reforms in the key markets will have a positive effect on market growth and offer the market's players lucrative opportunities for future growth. Additionally, the key players in the market are increasing their investments in R&D, which is fueling innovation in the global biosimilars market. New opportunities are opening as the patents on older biosimilar medications expire.

Restraints

High cost of R&D

Excessive costs associated with R&D capabilities, high manufacturing costs, and difficulties associated with medical procedures are anticipated to limit the growth of global biosimilars market. In addition, a lack of favorable reimbursement scenarios and technology penetration in developing economies, as well as a lack of definitive approval standards and suitable infrastructure in low- and middle-income countries, are anticipated to pose challenges to the market growth during the forecast period.

Impact of COVID-19 on Global Biosimilars Market

The COVID-19 outbreak had an impact on several global industries, and the biosimilars market is no exception. To slow the Covid-19 pandemic's rapid spread, administrative bodies worldwide implemented several measures, including lockdowns and strict social seclusion. The global closure of manufacturing facilities during the early stages of the pandemic hurt the biosimilars market. Small and medium-sized businesses, which are the main technology suppliers to the biosimilars industry, saw a sharp decline due to the pandemic. The restricted movement of people and goods because of the lockdown measures put in place during the early stages of the pandemic's spread also had an impact on the global biosimilars market. However, during the post COVID-19 pandemic period, the global market for biosimilars is expected to grow at an impressive growth rate as biosimilars provide significant cost savings to government and third-party payors.

Global Biosimilars Market

Segmental Coverage

Global Biosimilars Market - By Product

Global biosimilars market is divided into Monoclonal Antibodies (Infliximab, Rituximab, Trastuzumab), Insulin, Interferon, Etanercept, Glucagon, and Calcitonin. In 2021, the monoclonal antibodies market share was greater than 25%. Numerous illnesses, including cancer, rheumatoid arthritis, cardiovascular diseases, and multiple sclerosis, are treated with the help of monoclonal antibodies. Due to the widespread use of monoclonal antibodies in the treatment of cancer, which specifically targets specific infected cells, the Monoclonal Antibodies segment is expected to maintain its leadership position during the forecast period.

Global Biosimilars Market Share

Global Biosimilars Market - By Disease Indication

On basis of the disease indication, global biosimilars market is divided into Cancer, Auto Immune Diseases, Chronic Diseases, Blood Disorders, and other segments. The global market is expanding as chronic diseases are becoming more common. A growing number of people around the world are using biosimilar medications because of their affordability. During the forecast period, an increase in the number of cancer patients, chronic disease cases, and geriatric population growth are expected to drive up demand for biosimilars.

Over 70% of cancer deaths occur in low- and middle-income countries, making it the second leading cause of death worldwide. Age-related increases in cancer incidence are most likely caused by an increase in the risk of developing particular cancers as people age. In the coming years, the development of biosimilar medications for the treatment of chronic diseases is anticipated to drive the global biosimilar market.

Global Biosimilars Market - By Distribution Channel

On basis of the distribution channel, global biosimilar market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacies segment dominates the global biosimilars market by distribution channel.

Global Natural Fiber Composites Market - By Region

Geographically, global biosimilars market covers five major regions:  North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In terms of revenue, Europe dominated the global biosimilars market in 2021 and is expected to maintain its dominance during the forecast period. Europe accounts for about half of the market. The increased use of biosimilars in Europe has fueled market growth. Furthermore, regulatory authorities have played a significant role in the adoption of biosimilars by making appropriate and favorable changes toward biosimilar drug approval.

North America, on the other hand, is expected to grow at a rapid pace during the forecast period. The growing popularity of biosimilars in North America, as well as the presence of numerous market players in the region, are driving significant investments in biosimilar research, which is expected to drive the biosimilars market in the region.

Competitive Landscape

Global biosimilars market is fiercely competitive, with Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen. The key strategies used by these market leaders are new product launches, mergers & acquisitions, and alliances. To grow their market share, these companies are also focusing on investing in innovations, collaborations, and expansions.

Recent Development

  • In May 2022 - Biocon Biologics, along with Viatris Inc., launched Abevmy, a bevacizumab drug, in Canada. This drug is a biosimilar to Avastin, developed by Roche, and was approved by Health Canada for four oncology indications. The launch of this drug helped the company to further expand its oncology portfolio in Canada, thereby expanding patient access to cost-effective biologics for cancer treatment.

  • In September 2021 - Sandoz, a Novartis division, signed a commercialization agreement with Bio-Thera Solutions for the biosimilar BAT1706, bevacizumab. This agreement added to the Sandoz’s leading off-patent portfolio for oncology & helped in market expansion. The agreement helps the company to strike a perfect strategic balance between patient care and cost-effectiveness.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Billion

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Product/ Service Segmentation

Product, Disease Indication, Distribution Channel, Region

Key Players

Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Biogen.

 

By Product

  • Monoclonal Antibodies

  1. Infliximab

  2. Rituximab

  3. Trastuzumab

  • Insulin

  • Interferon

  • Etanercept

  • Glucagon

  • Calcitonin

By Disease Indication

  • Cancer

  • Auto Immune Diseases

  • Chronic Diseases

  • Blood Disorders

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Region

    • North America

    • Europe

    • Asia Pacific (APAC)

    • Latin America

    • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Biosimilars Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Rising prevalence of autoimmune diseases
        2. Increasing adoption of biosimilars
        3. Rising cost effectiveness of biosimilars
      2. Restraints
        1. Complexities in manufacturing
      3. Opportunity
        1. Rising research and development proficiencies
        2. Rising government investments on healthcare infrastructure
      4. Challenges
        1. Intense Competition
        2. High cost of R&D
    3. Technology Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Biosimilars Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
        1. Monoclonal Antibodies
          1. Infliximab
          2. Rituximab
          3. Trastuzumab
        2. Insulin
        3. Interferon
        4. Etanercept
        5. Glucagon
        6. Calcitonin
      2. By Disease Indication
        1. Cancer
        2. Auto-Immune Diseases
        3. Chronic Diseases
        4. Blood Disorders
        5. Others
      3. By Distribution Channel
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America
        5. Middle East and Africa (MEA)
  5. North America Biosimilars Market
      1. Market Size & Forecast, 2019–2029
      2. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
      4. By Country
        1. United States
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        2. Canada
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
  6. Europe Biosimilars Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
      4. By Country
        1. Germany
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        2. United Kingdom
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        3. Italy
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        4. France
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        5. Spain
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        6. The Netherlands
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        7. Belgium
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        8. NORDIC Countries
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        9. Rest of Europe
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
  7. Asia Pacific Biosimilars Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
      4. By Country
        1. China
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        2. India
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        3. Japan
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        4. South Korea
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        5. Australia & New Zealand
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        6. Indonesia
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        7. Malaysia
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        8. Singapore
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        9. Philippines
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        10. Vietnam
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        11. Rest of Asia Pacific
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
  8. Latin America Biosimilars Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
      4. By Country
        1. Brazil
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        2. Mexico
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        3. Argentina
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        4. Peru
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        5. Colombia
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        6. Rest of Latin America
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
  9.  Middle East & Africa Biosimilars Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product
      2. By Disease Indication
      3. By Distribution Channel
      4. By Country
        1. Saudi Arabia
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        2. UAE
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        3. Qatar
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        4. Kuwait
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        5. Iran
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        6. South Africa
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        7. Nigeria
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        8. Kenya
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        9. Egypt
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        10. Morocco
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        11. Algeria
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
        12. Rest of Middle East & Africa
          1. By Product
          2. By Disease Indication
          3. By Distribution Channel
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Biosimilars Company Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, and others)
  11. Impact of Covid-19 on Global Biosimilars Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Novartis AG
    2. Orion Pharma AB
    3. Pfizer Inc.
    4. Samsung Bioepis
    5. Coherus BioSciences, Inc.
    6. Amgen Inc.
    7. Eli Lilly and Company.
    8. Takeda Pharmaceutical Company Limited
    9. Bristol-Myers Squibb Company
    10. Merck KGaA
    11. Teva Pharmaceutical Industries Ltd.
    12. Biocon
    13. Bayer AG
    14. AbbVie Inc.
    15. Allergan
    16. Dr. Reddy’s Laboratories Ltd.
    17. Boehringer Ingelheim International GmbH
    18. Biogen
    19. Other Prominent Players
  13. Key Strategic Recommendations
  14. Research Methodology
    1. Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents, By Region
    5. Assumptions & Limitations

 

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

 

 

List of Figures

Figure 1        Global Biosimilars Market Segmentation

Figure 2        Global Biosimilars Market Value Chain Analysis

Figure 3        Company Market Share Analysis, 2022

Figure 4        Global Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 5        Global Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 6        Global Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 7        Global Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 8        Global Biosimilars Market Share, By Region, By Value, 2019–2029

Figure 9        North America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 10       North America Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 11       North America Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 12       North America Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 13       North America Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 14       United States Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 15       United States Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 16       United States Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 17       United States Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 18       Canada Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 19       Canada Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 20       Canada Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 21       Canada Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 22       Europe Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 23       Europe Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 24       Europe Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 25       Europe Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 26       Europe Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 27       Germany Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 28       Germany Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 29       Germany Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 30       Germany Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 31       UK Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 32       UK Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 33       UK Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 34       UK Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 35       Italy Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 36       Italy Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 37       Italy Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 38       Italy Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 39       France Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 40       France Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 41       France Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 42       France Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 43       Spain Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 44       Spain Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 45       Spain Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 46       Spain Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 47       The Netherlands Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 48       The Netherlands Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 49       The Netherlands Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 50       The Netherlands Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 51       Belgium Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 52       Belgium Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 53       Belgium Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 54       Belgium Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 55       NORDIC Countries Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 56       NORDIC Countries Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 57       NORDIC Countries Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 58       NORDIC Countries Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 59       Rest of Europe Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 60       Rest of Europe Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 61       Rest of Europe Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 62       Rest of Europe Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 63       Asia-Pacific Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 64       Asia-Pacific Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 65       Asia-Pacific Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 66       Asia-Pacific Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 67       Asia-Pacific Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 68       China Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 69       China Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 70       China Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 71       China Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 72       India Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 73       India Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 74       India Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 75       India Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 76       Japan Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 77       Japan Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 78       Japan Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 79       Japan Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 80       South Korea Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 81       South Korea Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 82       South Korea Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 83       South Korea Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 84       Australia & New Zealand Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 85       Australia & New Zealand Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 86       Australia & New Zealand Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 87       Australia & New Zealand Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 88       Indonesia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 89       Indonesia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 90       Indonesia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 91       Indonesia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 92       Malaysia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 93       Malaysia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 94       Malaysia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 95       Malaysia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 96       Singapore Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 97       Singapore Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 98       Singapore Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 99       Singapore Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 100     Philippines Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 101     Philippines Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 102     Philippines Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 103     Philippines Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 104     Vietnam Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 105     Vietnam Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 106     Vietnam Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 107     Vietnam Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 108     Rest of APAC Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 109     Rest of APAC Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 110     Rest of APAC Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 111     Rest of APAC Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 112     Latin America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 113     Latin America Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 114     Latin America Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 115     Latin America Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 116     Latin America Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 117     Brazil Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 118     Brazil Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 119     Brazil Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 120     Brazil Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 121     Mexico Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 122     Mexico Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 123     Mexico Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 124     Mexico Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 125     Argentina Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 126     Argentina Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 127     Argentina Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 128     Argentina Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 129     Peru Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 130     Peru Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 131     Peru Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 132     Peru Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 133     Colombia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 134     Colombia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 135     Colombia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 136     Colombia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 137     Rest of LATAM Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 138     Rest of LATAM Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 139     Rest of LATAM Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 140     Rest of LATAM Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 141     Middle East & Africa Biosimilars Market Size, By Value (USD Billion), 2019–2029

Figure 142     Middle East & Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 143     Middle East & Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 144     Middle East & Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 145     Middle East & Africa Biosimilars Market Share, By Country, By Value, 2019–2029

Figure 146     Saudi Arabia Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 147     Saudi Arabia Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 148     Saudi Arabia Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 149     Saudi Arabia Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 150     UAE Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 151     UAE Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 152     UAE Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 153     UAE Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 154     Qatar Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 155     Qatar Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 156     Qatar Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 157     Qatar Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 158     Kuwait Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 159     Kuwait Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 160     Kuwait Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 161     Kuwait Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 162     Iran Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 163     Iran Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 164     Iran Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 165     Iran Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 166     South Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 167     South Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 168     South Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 169     South Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 170     Nigeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 171     Nigeria Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 172     Nigeria Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 173     Nigeria Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 174     Kenya Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 175     Kenya Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 176     Kenya Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 177     Kenya Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 178     Egypt Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 179     Egypt Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 180     Egypt Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 181     Egypt Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 182     Morocco Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 183     Morocco Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 184     Morocco Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 185     Morocco Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 186     Algeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 187     Algeria Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 188     Algeria Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 189     Algeria Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

Figure 190     Rest of Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Figure 191     Rest of Middle East & Africa Biosimilars Market Share, By Product, By Value, 2019–2029

Figure 192     Rest of Middle East & Africa Biosimilars Market Share, By Disease Indication, By Value, 2019–2029

Figure 193     Rest of Middle East & Africa Biosimilars Market Share, By Distribution Channel, By Value, 2019–2029

           

List of Tables

Table 1         Global Biosimilars Market Size, By Product, By Value, 2019–2029

Table 2         Global Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 3         Global Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 4         Global Biosimilars Market Size, By Region, By Value, 2019–2029

Table 5         North America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 6         North America Biosimilars Market Size, By Product, By Value, 2019–2029

Table 7         North America Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 8         North America Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 9         North America Biosimilars Market Size, By Country, By Value, 2019–2029

Table 10        United States Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 11        United States Biosimilars Market Size, By Product, By Value, 2019–2029

Table 12        United States Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 13        United States Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 14        Canada Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 15        Canada Biosimilars Market Size, By Product, By Value, 2019–2029

Table 16        Canada Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 17        Canada Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 18        Europe Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 19        Europe Biosimilars Market Size, By Product, By Value, 2019–2029

Table 20        Europe Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 21        Europe Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 22        Europe Biosimilars Market Size, By Country, By Value, 2019–2029

Table 23        Germany Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 24        Germany Biosimilars Market Size, By Product, By Value, 2019–2029

Table 25        Germany Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 26        Germany Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 27        UK Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 28        UK Biosimilars Market Size, By Product, By Value, 2019–2029

Table 29        UK Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 30        UK Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 31        Italy Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 32        Italy Biosimilars Market Size, By Product, By Value, 2019–2029

Table 33        Italy Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 34        Italy Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 35        France Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 36        France Biosimilars Market Size, By Product, By Value, 2019–2029

Table 37        France Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 38        France Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 39        Spain Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 40        Spain Biosimilars Market Size, By Product, By Value, 2019–2029

Table 41        Spain Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 42        Spain Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 43        The Netherlands Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 44        The Netherlands Biosimilars Market Size, By Product, By Value, 2019–2029

Table 45        The Netherlands Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 46        The Netherlands Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 47        Belgium Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 48        Belgium Biosimilars Market Size, By Product, By Value, 2019–2029

Table 49        Belgium Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 50        Belgium Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 51        NORDIC Countries Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 52        NORDIC Countries Biosimilars Market Size, By Product, By Value, 2019–2029

Table 53        NORDIC Countries Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 54        NORDIC Countries Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 55        Rest of Europe Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 56        Rest of Europe Biosimilars Market Size, By Product, By Value, 2019–2029

Table 57        Rest of Europe Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 58        Rest of Europe Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 59        Asia-Pacific Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 60        Asia-Pacific Biosimilars Market Size, By Product, By Value, 2019–2029

Table 61        Asia-Pacific Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 62        Asia-Pacific Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 63        Asia-Pacific Biosimilars Market Size, By Country, By Value, 2019–2029

Table 64        China Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 65        China Biosimilars Market Size, By Product, By Value, 2019–2029

Table 66        China Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 67        China Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 68        India Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 69        India Biosimilars Market Size, By Product, By Value, 2019–2029

Table 70        India Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 71        India Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 72        Japan Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 73        Japan Biosimilars Market Size, By Product, By Value, 2019–2029

Table 74        Japan Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 75        Japan Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 76        South Korea Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 77        South Korea Biosimilars Market Size, By Product, By Value, 2019–2029

Table 78        South Korea Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 79        South Korea Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 80        Australia & New Zealand Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 81        Australia & New Zealand Biosimilars Market Size, By Product, By Value, 2019–2029

Table 82        Australia & New Zealand Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 83        Australia & New Zealand Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 84        Indonesia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 85        Indonesia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 86        Indonesia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 87        Indonesia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 88        Malaysia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 89        Malaysia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 90        Malaysia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 91        Malaysia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 92        Singapore Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 93        Singapore Biosimilars Market Size, By Product, By Value, 2019–2029

Table 94        Singapore Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 95        Singapore Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 96        Philippines Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 97        Philippines Biosimilars Market Size, By Product, By Value, 2019–2029

Table 98        Philippines Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 99        Philippines Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 100      Vietnam Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 101      Vietnam Biosimilars Market Size, By Product, By Value, 2019–2029

Table 102      Vietnam Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 103      Vietnam Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 104      Rest of APAC Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 105      Rest of APAC Biosimilars Market Size, By Product, By Value, 2019–2029

Table 106      Rest of APAC Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 107      Rest of APAC Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 108      Latin America Biosimilars Market Size, By Value (USD Billion), 2019–2029

Table 109      Latin America Biosimilars Market Size, By Product, By Value, 2019–2029

Table 110      Latin America Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 111      Latin America Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 112      Latin America Biosimilars Market Size, By Country, By Value, 2019–2029

Table 113      Brazil Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 114      Brazil Biosimilars Market Size, By Product, By Value, 2019–2029

Table 115      Brazil Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 116      Brazil Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 117      Mexico Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 118      Mexico Biosimilars Market Size, By Product, By Value, 2019–2029

Table 119      Mexico Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 120      Mexico Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 121      Argentina Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 122      Argentina Biosimilars Market Size, By Product, By Value, 2019–2029

Table 123      Argentina Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 124      Argentina Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 125      Peru Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 126      Peru Biosimilars Market Size, By Product, By Value, 2019–2029

Table 127      Peru Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 128      Peru Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 129      Colombia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 130      Colombia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 131      Colombia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 132      Colombia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 133      Rest of LATAM Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 134      Rest of LATAM Biosimilars Market Size, By Product, By Value, 2019–2029

Table 135      Rest of LATAM Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 136      Rest of LATAM Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 137      Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 138      Middle East & Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 139      Middle East & Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 140      Middle East & Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 141      Middle East & Africa Biosimilars Market Size, By Country, By Value, 2019–2029

Table 142      Saudi Arabia Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 143      Saudi Arabia Biosimilars Market Size, By Product, By Value, 2019–2029

Table 144      Saudi Arabia Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 145      Saudi Arabia Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 146      UAE Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 147      UAE Biosimilars Market Size, By Product, By Value, 2019–2029

Table 148      UAE Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 149      UAE Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 150      Qatar Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 151      Qatar Biosimilars Market Size, By Product, By Value, 2019–2029

Table 152      Qatar Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 153      Qatar Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 154      Kuwait Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 155      Kuwait Biosimilars Market Size, By Product, By Value, 2019–2029

Table 156      Kuwait Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 157      Kuwait Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 158      Iran Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 159      Iran Biosimilars Market Size, By Product, By Value, 2019–2029

Table 160      Iran Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 161      Iran Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 162      South Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 163      South Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 164      South Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 165      South Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 166      Nigeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 167      Nigeria Biosimilars Market Size, By Product, By Value, 2019–2029

Table 168      Nigeria Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 169      Nigeria Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 170      Kenya Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 171      Kenya Biosimilars Market Size, By Product, By Value, 2019–2029

Table 172      Kenya Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 173      Kenya Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 174      Egypt Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 175      Egypt Biosimilars Market Size, By Product, By Value, 2019–2029

Table 176      Egypt Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 177      Egypt Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 178      Morocco Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 179      Morocco Biosimilars Market Size, By Product, By Value, 2019–2029

Table 180      Morocco Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 181      Morocco Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 182      Algeria Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 183      Algeria Biosimilars Market Size, By Product, By Value, 2019–2029

Table 184      Algeria Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 185      Algeria Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 186      Rest of Middle East & Africa Biosimilars Market Size, By Value (USD Million), 2019–2029

Table 187      Rest of Middle East & Africa Biosimilars Market Size, By Product, By Value, 2019–2029

Table 188      Rest of Middle East & Africa Biosimilars Market Size, By Disease Indication, By Value, 2019–2029

Table 189      Rest of Middle East & Africa Biosimilars Market Size, By Distribution Channel, By Value, 2019–2029

Table 190      Novartis AG Company Overview

Table 191      Novartis AG Financial Overview

Table 192      Orion Pharma AB Company Overview

Table 193      Orion Pharma AB Financial Overview

Table 194      Pfizer Inc.  Company Overview

Table 195      Pfizer Inc.  Financial Overview

Table 196      Samsung Bioepis Company Overview

Table 197      Samsung Bioepis Financial Overview

Table 198      Coherus BioSciences, Inc.  Company Overview

Table 199      Coherus BioSciences, Inc.  Financial Overview

Table 200      Amgen Inc. Company Overview

Table 201      Amgen Inc. Financial Overview

Table 202      Eli Lilly and Company Overview

Table 203      Eli Lilly and Company Financial Overview

Table 204      Takeda Pharmaceutical Company Limited Company Overview

Table 205      Takeda Pharmaceutical Company Limited Financial Overview

Table 206      Bristol-Myers Squibb Company Overview

Table 207      Bristol-Myers Squibb Company Financial Overview

Table 208      Merck KGaA Company Overview

Table 209      Merck KGaA Financial Overview

Table 210      Teva Pharmaceutical Industries Ltd.  Company Overview

Table 211      Teva Pharmaceutical Industries Ltd.  Financial Overview

Table 212      Biocon Company Overview

Table 213      Biocon Financial Overview

Table 214      Bayer AG Company Overview

Table 215      Bayer AG Financial Overview

Table 216      AbbVie Inc.  Company Overview

Table 217      AbbVie Inc.  Financial Overview

Table 218      Allergan Company Overview

Table 219      Allergan Financial Overview

Table 220      Dr. Reddy’s Laboratories Ltd.  Company Overview

Table 221      Dr. Reddy’s Laboratories Ltd.  Financial Overview

Table 222      Boehringer Ingelheim International GmbH Company Overview

Table 223      Boehringer Ingelheim International GmbH Financial Overview

Table 224      Biogen Company Overview

Table 225      Biogen Financial Overview

Market Segmentation

By Product

  • Monoclonal Antibodies

  1. Infliximab

  2. Rituximab

  3. Trastuzumab

  • Insulin

  • Interferon

  • Etanercept

  • Glucagon

  • Calcitonin

By Disease Indication

  • Cancer

  • Auto Immune Diseases

  • Chronic Diseases

  • Blood Disorders

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Region

    • North America

    • Europe

    • Asia Pacific (APAC)

    • Latin America

    • Middle East and Africa (MEA)

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Biosimilars Market size is estimated at 28.88 billion in 2022.
Ans: Major factors driving the growth of Global Biosimilars Market include rising autoimmune disease prevalence, rising biosimilar adoption, rising biosimilar cost-effectiveness, rising research and development skills, and rising government spending on healthcare infrastructure.
Ans: The retail pharmacies segment holds the highest market share in the Global Biosimilars Market by distribution channel.
Ans: The monoclonal antibodies segment accounts for the highest market share in the global biosimilars market by product.
Ans: Key players in Global Biosimilars Market include Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon., Bayer AG, AbbVie Inc., Allergan, Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen. 
array(1) {
  ["__ci_last_regenerate"]=>
  int(1732213967)
}